Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Void who wrote (23204)	7/14/1998 9:20:00 PM
From: Hippieslayer	Read Replies (1) \| Respond to of 32384

Nice catch. I wonder why this was never addressed by those in the know?

To: Void who wrote (23204)	7/15/1998 8:28:00 AM
From: Henry Niman	Respond to of 32384

Void, I think that LGND plans on moving the human-reactive mimics into the clinic. I haven't had a chance to read the BioWorld report. I noticed that in your post LGND was exploring "several drawing boards". Was Rosen talking about different series for G-CSF (Neupogen) or did he mention additional targets (like Epogen, Thrombopoietin, and Leptin)? The above are clearly within the SBH alliance, but of course LGND's approach can be applied to virtually any polypeptide hormone. Robinson had indicated that SBH was "gobbling up LGND's targets", suggesting that the alliance was expanding and broadening. Did the BioWorld article discuss the breadth of LGND's programs? Back in Feb (see links to home.att.net ) I had said that the mouse mimic was being put out for publication and patent purposes, but I suspected that the human reactive mimics would be kept secret for as long as possible. The quote that you put up seems to indicate that LGND isn't saying much beyond the Science paper. Any more details?

To: Void who wrote (23204)	7/15/1998 5:33:00 PM
From: Henry Niman	Read Replies (4) \| Respond to of 32384

Void, I have now had a chance to read the entire article and the quote that you posted is really the only info on species specificity. I have re-read the paragraph and Rosen does seem to be just talking about SB247464, when he discusses the mouse specificity. When he talks about the "several drawing boards", he does not indicate that they have not found a human-active compound when these other avenues were explored. The article does address your question about SB247464 moving into the clinic, and LGND indicates that the molecule will be used to explore its mechanism of action (in mice) and its structure will provide a prototype to find related molecules that are human-active. As I said in February, I think that LGND does have a human-active compound(s) and it is in pre-clinical testing (which seems to be borne out by the pipeline table at home.att.net which indicates that a compound has been identified and SELECTED. Robinson's comments on SBH "gobbling up" LGND's targets also supports the conclusion that the programs offer considerable promise and they are move forward and expanding at a rapid rate.